WG
VNDA icon

Winton Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Winton Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Sell
33,800
-11,000
-25% -$71.9K 0.01% 1014
2026
Q1 		$310K Buy
+44,800
New +$345K 0.01% 854
2024
Q4 		– Sell
-72,465
Closed -$340K – 794
2024
Q3 		$340K Sell
72,465
-41,018
-36% -$220K 0.02% 498
2024
Q2 		$641K Sell
113,483
-50,343
-31% -$260K 0.04% 389
2024
Q1 		$673K Buy
163,826
+50,734
+45% +$203K 0.05% 428
2023
Q4 		$477K Buy
113,092
+25,599
+29% +$103K 0.03% 339
2023
Q3 		$378K Buy
87,493
+2,293
+3% +$12.7K 0.03% 433
2023
Q2 		$561K Buy
85,200
+19,331
+29% +$124K 0.05% 276
2023
Q1 		$447K Sell
65,869
-5,093
-7% -$35.8K 0.03% 729
2022
Q4 		$524K Buy
70,962
+17,585
+33% +$171K 0.03% 611
2022
Q3 		$527K Sell
53,377
-23,805
-31% -$251K 0.03% 628
2022
Q2 		$841K Buy
77,182
+59
+0.1% +$611 0.04% 536
2022
Q1 		$872K Buy
77,123
+20,101
+35% +$264K 0.05% 513
2021
Q4 		$895K Sell
57,022
-13,270
-19% -$231K 0.05% 499
2021
Q3 		$1.21M Sell
70,292
-11,286
-14% -$198K 0.07% 408
2021
Q2 		$1.75M Sell
81,578
-8,329
-9% -$149K 0.09% 236
2021
Q1 		$1.35M Sell
89,907
-9,050
-9% -$147K 0.08% 307
2020
Q4 		$1.3M Sell
98,957
-178,244
-64% -$2.15M 0.09% 278
2020
Q3 		$2.68M Sell
277,201
-308,047
-53% -$3.29M 0.09% 391
2020
Q2 		$6.7M Buy
585,248
+21,725
+4% +$246K 0.17% 121
2020
Q1 		$5.84M Buy
563,523
+10,883
+2% +$135K 0.15% 189
2019
Q4 		$9.07M Buy
552,640
+529,686
+2,308% +$8.01M 0.13% 269
2019
Q3 		$305K Buy
+22,954
New +$320K ﹤0.01% 1274

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's VNDA Position: Q2 2026 in Review

Winton Group reduced its Vanda Pharmaceuticals (VNDA) stake by 25% in Q2 2026, selling an estimated $71.9K and leaving 33,800 shares worth $207K. The position accounts for 0.01% of the portfolio, ranked #1014.

Winton Group first reported a position in VNDA in Q3 2019 and has held it in 23 quarters since. The position peaked at $9.07M in Q4 2019. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Winton Group held 33,800 shares of Vanda Pharmaceuticals worth $207K as of Q2 2026.
  • Winton Group sold 11,000 Vanda Pharmaceuticals shares in Q2 2026, an estimated $71.9K.
  • Vanda Pharmaceuticals made up 0.01% of Winton Group's portfolio in Q2 2026, its #1014 holding.
  • Winton Group first reported a position in Vanda Pharmaceuticals in Q3 2019 and has held it in 23 quarters since.
  • Winton Group's Vanda Pharmaceuticals position peaked at $9.07M in Q4 2019.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.